



CIN : L74110HP2004LC027558

14th February, 2023

To

**The Listing Department
Bombay Stock Exchange Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai – 400001**

**The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G
Bandra Kurla Complex
Mumbai – 400051**

Trading Symbol: JHS

Scrip Code: 532771

Subject: Outcome of the Board Meeting held on February 14, 2023

Ref.: Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

In terms of above referred provisions, this is to inform that the Board of Directors of JHS Svendgaard Laboratories Limited (“**the Company**”) at their meeting held on today i.e. 14th February 2023, inter-alia, considered and approved, the Unaudited Financial Results (Standalone as well as Consolidated) for the quarter and nine months ended 31st December 2022.

Enclosed are the following documents in respect of the items transacted in the meeting:

- a. The Un-audited Financial Results of the Company (Standalone as well as Consolidated) for the quarter and nine months ended 31st December 2022. (**Annexure- A**).
- b. Limited Review Reports issued by the Statutory Auditors on such Financial Results. (**Annexure- B**).

In the same meeting, the Board of Directors took on record the resignation of Mr. Neeraj Kumar from the post of Joint Chief Financial Officer due to personal reasons. The Company shall be relieving him from his responsibilities with effect from March 15, 2023 as per the Company’s Policy and requisite update in this connection will be submitted to the stock exchanges in due course.



CIN : L74110HP2004LC027558

The Board meeting commenced at 12:00 P.M. and concluded at 04:00 P.M.

This disclosure along with the enclosures shall be made available on the website of the Company viz., <https://www.svendgaard.com>.

Kindly take the same on records.

**Thanking You,
For JHS Svendgaard Laboratories Limited**

**Komal Jha
Company Secretary & Compliance officer**

Encl: A/a

Review Report

To

The Board of Directors
JHS Svendgaard Laboratories Limited
B - 1/E-23, Mohan Co-operative Industrial Estate,
Mathura Road, New Delhi - 110044

1. We have reviewed the Standalone Unaudited Financial Results of JHS Svendgaard Laboratories Limited ("the Company") for the quarter ended 31 December 2022 and the year to date results for the period 1 April 2022 to 31 December 2022, which are included in the accompanying Statement of Standalone Unaudited Financial Results for the Quarter and nine months ended 31 December 2022' (the "Statement"). The Statement has been prepared by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. The Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For TATTVAM & Co.
Chartered Accountants
Firm's Registration No. 015048N


Gaurav Saraf
Partner

Membership No. 535310*



UDIN: 23535309BGZAZR6032
Place: New Delhi
Date: 14.02.2023

JHS SVENDGAARD LABORATORIES LIMITED

Regd. Office: Trilokpur Road, Kheri (Kala-Amb), Tehsil Nahau, Distt. Sirmour, Himachal Pradesh - 173030, INDIA

CIN-L74110HP2004PLC027558

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022

(Rs. in lakhs)

S.No.	Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Nine Month	Nine Month	Year Ended
		31st Dec 2022	30th Sep 2022	31st Dec 2021	Ended 31st Dec 2022	Ended 31st Dec 2021	31st March 2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	(a) Revenue from operations	2,125.52	2,085.20	1,934.43	6,131.19	6,265.42	7,990.59
	(b) Other income	141.36	288.75	242.00	548.76	613.53	814.39
	Total income	2,266.88	2,373.95	2,176.41	6,679.95	6,878.97	8,804.98
2	Expenses						
	(a) Cost of materials consumed	1,350.58	1,574.45	1,295.01	4,177.00	4,198.79	5,368.24
	(b) Purchases of stock-in-trade	0.79	2.31	-	3.10	61.94	63.97
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	184.04	(77.56)	71.74	255.68	253.34	253.45
	(d) Employee benefits expense	254.34	236.89	264.49	742.14	740.42	993.28
	(e) Finance costs	12.21	8.29	13.49	32.16	35.82	49.94
	(f) Depreciation and amortisation expenses	141.37	143.84	149.72	425.73	445.24	589.65
	(g) Other expenses	500.64	545.98	317.71	1,410.42	964.36	1,294.05
	Total expenses	2,443.96	2,434.20	2,112.14	7,046.23	6,699.91	8,612.59
3	Profit/(loss) before exceptional items and tax (1-2)	(177.08)	(60.25)	64.27	(366.29)	179.06	192.39
4	Exceptional items	-	-	-	-	-	-
5	Profit/(loss) before tax (3+4)	(177.08)	(60.25)	64.27	(366.29)	179.06	192.39
6	Tax expense/(income)						
	Current Tax	-	-	15.66	-	72.49	92.09
	Deferred Tax (including MAT Credit Entitlement)	2.41	(1.66)	2.34	204.04	(17.91)	342.97
	Tax for earlier years	-	-	-	-	-	1.50
7	Net Profit/(loss) for the period (5-6)	(179.49)	(58.59)	46.27	(570.34)	124.48	(244.17)
8	Other comprehensive income						
(a)	-Items that will not be reclassified to profit or loss	1.44	1.44	1.63	4.32	4.90	5.76
	-Income tax relating to items that will not be reclassified to profit or loss	(0.40)	(0.40)	(0.45)	(1.20)	(1.36)	(1.60)
(b)	-Items that will be reclassified to profit or loss	-	-	-	-	-	-
	-Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
9	Total comprehensive income for the period (7+8)	(178.45)	(57.56)	47.45	(567.22)	128.02	(240.01)
10	Paid-up equity share capital (Face value per share Rs. 10/-)	6,490.05	6,490.05	6,440.05	6,490.05	6,440.05	6,490.05
11	Reserve excluding revaluation reserves as per balance sheet of previous accounting year						
12	Earnings per equity share						
(a)	Basic (Rs.)	(0.28)	(0.09)	0.07	(0.88)	0.19	(0.38)
(b)	Diluted (Rs.)	(0.28)	(0.09)	0.07	(0.88)	0.19	(0.38)

Notes:

- 1 The above unaudited standalone financial results for the quarter 31st December 2022 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 14.02 2023. The figures for the quarter and nine months ended 31st December 2022 have been subjected to limited review by the statutory auditor.
- 2 The standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 3 In line with the provisions of Ind AS 108 - Operating Segments and on the basis the review of operations being done by the Management, the operations of the Company fall under Manufacturing of Oral Care products, which is considered to be the only reportable segment by the management.
- 4 The Company in its board meeting held on 09th October, 2020 has approved the Composite Scheme of Arrangement for Amalgamation and Demerger between among JHS Svendgaard Laboratories Limited (Demerged Company/ Transferee Company), JHS Svendgaard Retail Ventures Private Limited (Resulting Company) and JHS Svendgaard Brands Limited (Transferor Company) ('Composite Scheme') under Section 230-232 of the Companies Act, 2013. Thereafter, on 8th December, 2021, both the stock exchanges viz. BSE Limited and National Stock Exchange of India Limited had granted their no-objection to the Composite Scheme. The next date of hearing of the petition shall be on 1st March, 2023 for the consideration of the approval of the scheme.
- 5 Pursuant to approval of shareholders by way of special resolution in accordance with section 42 & 62 of the Companies Act, 2013 and Rules made thereunder and as per SEBI (ICDR) Regulations, 2018 the Company approved preferential allotment of 40,00,000 fully convertible warrants of Rs. 10 each at an issue price of Rs. 20 per warrant. Out of this 35,00,000 equity shares were listed with stock exchange in 9th March 2021 and balance 5,00,000 equity shares were listed with NSE and BSE on 9th May, 2022 and 12th May, 2022 respectively.
- 6 Previous period figures have been re-grouped / re-classified wherever necessary, to conform to current period's classification or also in order to comply with the requirements of the Schedule III to the Companies Act, 2013 effective 1st April, 2021.

Place : New Delhi

Date : 14th February ,2023

For and on behalf of Board of Directors



Nikhil Nanda
Managing Director
DIN : 00051501





Review Report

To:

The Board of Directors
JHS Svendgaard Laboratories Limited
B - 1/E-23, Mohan Co-operative Industrial Estate,
Mathura Road, New Delhi - 110044

1. We have reviewed the Consolidated Unaudited Financial Results of JHS Svendgaard Laboratories Limited ("the Parent") and its subsidiaries (the parent and its subsidiaries hereinafter referred to as the "Group"), [refer to Note 3 on the Statement] for the quarter ended 31 December 2022 and the year to date results for the period 1 April 2022 to 31 December 2022, which are included in the accompanying Statement of Consolidated Unaudited Financial Results for the quarter and nine months ended 31 December 2022 ("the Statement"). The Statement is being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"), which has been initiated by us for identification purposes.
2. The Statement, which is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:


Sr.no.	Name of Entities	Relationship
1	JHS Svendgaard Laboratories Limited	Parent
2	JHS Svendgaard Brands Limited (formerly known as JHS Svendgaard Dental Care Limited)	Subsidiary by virtue of Control
3	JHS Svendgaard Mechanical and Warehouse Private Limited	Subsidiary
4	JHS Svendgaard Retail Ventures Private Limited	Subsidiary



5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of three subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect total revenues of Rs. 395.56 lakhs and Rs. 1,051.63 lakhs, total net loss after tax of Rs. (28.72) lakhs and Rs. (86.41) lakhs and total comprehensive income of Rs. (28.72) lakhs and Rs. (85.49) lakhs for the quarter ended 31 December 2022 and for the period from 1 April 2022 to 31 December 2022, as considered in the consolidated unaudited financial results. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

For TATTVAM & Co.
Chartered Accountants
Firm's Registration No. 015048N



Gautav Saraf
Partner
Membership No. 535309



UDIN: 23535309BGZAZQ1071
Place: New Delhi
Date: 14.02.2023

JHS SVENDGAARD LABORATORIES LIMITED

Regd. Office: Trilokpur Road, Kheri (Kala-Amb), Tehsil Nahani, Distt. Sirmour, Himachal Pradesh - 173030, INDIA

CIN-L74110HP2004PLC027558

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022

(Rs. in lakhs)

S.No.	Particulars	Quarter Ended	Quarter	Quarter	Nine Month	Nine Month	Year
		31st Dec 2022	Ended 30th Sep 2022	Ended 31st Dec 2021	Ended 31st Dec 2022	Ended 31st Dec 2021	Ended 31st March 2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	(a) Revenue from operations	2,544.64	2,405.29	2,091.37	7,080.81	6,713.79	8,625.24
	(b) Other income	167.20	343.80	273.92	658.74	700.97	938.99
	Total income	2,711.85	2,749.09	2,365.29	7,739.54	7,414.76	9,564.23
2	Expenses						
	(a) Cost of materials consumed	1,350.58	1,574.45	1,295.00	4,177.00	4,198.79	5,368.24
	(b) Purchase of stock-in-trade	196.41	95.91	111.75	425.98	274.56	419.84
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	176.39	(78.13)	104.99	259.13	303.94	262.17
	(d) Employee benefits expense	436.02	403.11	303.50	1,174.83	858.16	1,144.56
	(e) Finance Costs	24.53	18.77	27.28	65.28	78.44	139.36
	(f) Depreciation and amortisation expense	170.95	174.16	171.35	515.32	536.65	705.22
	(g) Other expenses	569.12	658.85	389.55	1,668.84	1,147.94	1,514.54
	Total expenses	2,924.01	2,847.12	2,403.42	8,286.37	7,398.48	9,553.93
3	Profit / (Loss) before exceptional Items and tax (1-2)	(212.16)	(98.03)	(38.13)	(546.84)	16.28	10.30
4	Exceptional items						
5	Profit / (Loss) before tax (3+4)	(212.16)	(98.03)	(38.13)	(546.84)	16.28	10.30
6	Tax expense/(income)						
	Current Tax	-	-	15.66	-	72.49	92.09
	Deferred Tax (including MAT Credit Entitlement)	-3.95	(57.30)	(51.32)	117.92	(72.19)	345.65
	Tax for earlier years						1.50
7	Net Profit / (Loss) for the period (5-6)	(208.21)	(40.73)	(2.47)	(664.76)	15.98	(428.94)
8	Other comprehensive income						
(a)	-Items that will not be reclassified to profit or loss	1.44	1.44	3.02	5.57	9.05	10.75
	-Income tax relating to items that will not be reclassified to profit or loss	(0.40)	(0.40)	(0.81)	(1.53)	(2.44)	(2.90)
(b)	-Items that will be reclassified to profit or loss	-	-	-	-	-	-
	-Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
9	Total comprehensive income (7+8)	(207.16)	(39.68)	(0.26)	(660.73)	22.57	(421.09)
	Net profit attributable to:						
	Owners of the Company	(152.82)	(21.63)	26.52	(558.98)	30.57	(405.19)
	Non-controlling interest	-55.39	(19.10)	(29.01)	(105.76)	(14.60)	(23.74)
	Other Comprehensive Income attributable to:						
	Owners of the Company	1.04	1.04	1.63	3.51	4.85	5.73
	Non-controlling interest	-	-	0.59	0.53	1.76	2.12
	Total Comprehensive Income attributable to:						
	Owners of the Company	-151.78	(20.59)	28.15	(555.47)	35.42	(399.46)
	Non-controlling interest	-55.39	(19.10)	(28.41)	(105.23)	(12.84)	(21.63)
10	Paid-up equity share capital (Face value per share Rs. 10/-)	6,490.05	6,490.05	6,440.05	6,490.05	6,440.05	6,490.05
11	Reserve excluding revaluation reserves as per balance sheet of previous accounting year						
12	Earnings per equity share						
(a)	Basic (Rs.)	(0.24)	(0.03)	0.04	(0.86)	0.05	(0.63)
(b)	Diluted (Rs.)	(0.24)	(0.03)	0.04	(0.86)	0.05	(0.63)



Notes:

- The above unaudited standalone financial results for the quarter 31st December 2022 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 14.02.2023. The figures for the quarter and nine months ended 31st December 2022 have been subjected to limited review by the statutory auditor.
- The consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- The consolidated financial results of the Group include financials of three subsidiaries namely JHS Svendgaard Brands Limited (formerly known as JHS Svendgaard Dental Care Limited), JHS Svendgaard Mechanical and Warehouse Private Limited & JHS Svendgaard Retail Ventures Private Limited. The details of ownership is given as below :-

Particulars	As on 31st December, 2022	As on 31st March, 2022
JHS Svendgaard Brands Limited *	42.68%	42.68%
JHS Mechanical and Warehouse Private Limited	99.99%	99.99%
JHS Svendgaard Retail Ventures Private Limited	99.82%	99.82%

* JHS Svendgaard Brands Limited has been consolidated as per the requirement of Ind AS 110 "Consolidated financial statements" as it meets the criteria of "Control" definition as given in the standard. There are no changes except shareholding in the results as it was considered as subsidiary in earlier years.

- In line with the provisions of Ind AS 108 - Operating Segments and on the basis the review of operations being done by the Management, The Following disclosures have been made to enable users of financials instruments for better understanding of business of group.

Particulars	Quarter Ended 31st Dec 2022	Quarter Ended 30th Sep 2022	Quarter Ended 31st Dec 2021	Nine Month Ended 31st Dec 2022	Nine Month Ended 31st Dec 2021	Year Ended 31st March 2022
Segment Revenue						
Manufacturing business	2,125.52	2,085.20	1,934.43	6,131.19	6,265.42	7,990.59
Other than manufacturing	101.51	101.51	121.18	280.19	379.48	498.20
Retail business	299.85	299.85	85.61	771.44	184.74	274.55
Less: Inter segment revenue	(81.27)	(81.27)	(49.85)	(125.58)	(115.86)	(138.11)
Segment Results						
Manufacturing business	(179.49)	(58.60)	46.27	(570.33)	124.48	(244.16)
Other than manufacturing	(33.50)	(33.50)	(50.66)	(185.13)	(25.40)	(41.55)
Retail business	50.84	50.84	2.34	98.72	(74.06)	(134.67)
Less: Inter segment result	0.52	0.52	(0.42)	(8.02)	(9.04)	(8.56)
Segment Assets						
Manufacturing business	20,915.28	21,105.77	21,497.89	20,915.28	21,497.89	21,108.91
Other than manufacturing	6,866.69	6,240.96	4,302.22	6,866.69	4,302.22	6,247.06
Retail business	851.44	1,018.60	746.96	851.44	746.96	745.12
Less: Inter segment assets	(5,936.15)	(5,936.15)	(249.41)	(5,936.15)	(249.41)	(5,901.91)
Segment Liabilities						
Manufacturing business	2,505.93	2,517.97	2,227.49	2,505.93	2,227.49	2,132.32
Other than manufacturing	5,494.03	4,771.31	2,729.58	5,494.03	2,729.58	4,690.65
Retail business	382.69	597.94	316.34	382.69	316.34	375.09
Less: Inter segment liabilities	(4,538.22)	(4,538.22)	(1,319.52)	(4,538.22)	(1,319.52)	(4,503.44)

- The Company in its board meeting held on 09th October, 2020 has approved the Composite Scheme of Arrangement for Amalgamation and Demerger between among JHS Svendgaard Laboratories Limited (Demerged Company/ Transferee Company), JHS Svendgaard Retail Ventures Private Limited (Resulting Company) and JHS Svendgaard Brands Limited (Transferor Company) ("Composite Scheme") under Section 230-232 of the Companies Act, 2013. Thereafter, on 8th December, 2021, both the stock exchanges viz. BSE Limited and National Stock Exchange of India Limited had granted their no-objection to the Composite Scheme. The next date of hearing of the petition shall be on 1st March 2023 for the consideration of the approval of the scheme.
- Pursuant to approval of shareholders by way of special resolution in accordance with section 42 & 62 of the Companies Act, 2013 and Rules made thereunder and as per SEBI (ICDR) Regulations, 2018 the Company approved preferential allotment of 40,00,000 fully convertible warrants of Rs. 10 each at an issue price of Rs. 20 per warrant. Out of this 35,00,000 equity shares were listed with stock exchange in 9th March 2021 and balance 5,00,000 equity shares were listed with NSE and BSE on 09th May, 2022 and 12th May, 2022 respectively.
- Previous period figures have been re-grouped / re-classified wherever necessary, to conform to current period's classification or also in order to comply with the requirements of the Schedule III to the Companies Act, 2013 effective 1st April, 2021.

For and on behalf of Board of Directors

Nikhil Nanda
Managing Director
DIN : 00051501

Place : New Delhi

Date : 14th February, 2023